NEW YORK (GenomeWeb News) – GE Healthcare company Clarient and Acorn Research today announced a collaboration targeting the molecular testing of tumor samples.
The collaboration, the terms of which were not disclosed, brings together Clarient's expertise in cancer diagnostics and Acorn's oncology network and advanced bioinformatics platform, they said.
The firms will create standardized testing protocols across the Acorn network of oncology community practices and hospitals "with treatment guidelines and clinical trial opportunities," in the hope of delivering individualized targeted treatments based on specific genetic markers. A system for collecting tumor specific biomarker data when patients are initially diagnosed with cancer will also be established.
The collaboration, the firms said, will enable the matching of biomarker data with outcomes data for clinical trials and clinical practice to identify new prognostic biomarkers and biomarker-specific treatments.
Discovering new biomarkers that could lead to the treatment of cancer on an individualized basis "has the potential to improve mortality rates, enhance patient quality of life, and reduce the cost of burden on cancer treatment to both patients and payers," Ron Andrews, CEO of Clarient, said in a statement.